Biotech News
Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results
investors.adaptivebiotech.com2026-05-06 14:55 EST
Full year MRD revenue growth of 46% driven by clonoSEQ® testing volume SEATTLE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to